🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- M96883109
- Market Cap
- Micro Cap
- IPO
- 9/30/2014 · $6.00/share
Business: Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune- inflammatory diseases. The Company's clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company, has developed two programs based on these platforms; an oncology program and an anti-inflammatory program.
Notes: July 30, 2014, The Company entered into an underwriting agreement for its initial public offering. However, that underwriting agreement was terminated on August 7, 2014 by those underwriters party thereto prior to closing, after one of its existing shareholders did not fund payment for shares it had previously agreed to purchase in the offering. Shares had begun trading on The NASDAQ Global Market on a when-issued basis under the ticker symbol VBLX. As a result of the termination of the underwriting agreement, trading was terminated and no shares were issued. The Preliminary Prospectus describes a revised offering of our shares. Following the execution of a new underwriting agreement with the underwriters, we anticipate our shares trading on The NASDAQ Global Market under a new ticker symbol, VBLT.
Company Contact
- CEO
- Dror Harats
- CFO
- Sam Backenroth
- Investor Relations
- Daniel Ferry, LifeSci Advisors · 617-430-7576 · daniel@lifesciadvisors.com